Biotech wins $16.5 million in drug royalties dispute
Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.
In conversation with...Beatriz San Martin, Arnold & Porter
The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.
Pharma company raises pressure with hypotension drug lawsuit
Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.
Teva breached antitrust rules over Copaxone, says EU
European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.
French pharma firm inks deal with tech provider
The partnership aims to progress drug discovery and development | Tech platform accelerates trials and provides higher quality trial data.
DNA test-maker demands $817m triple damages in patent win
Dispute against LabCorp claims wilful infringement | Plaintiff has also sued Illumina, Roche and Myriad in separate cases.
Generic maker hits back at Novartis stay bid
HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.
Patent pool inks major COVID-19 deal with Japanese company
Antiviral treatment could potentially be distributed across 117 countries | MPP looks for interest from potential sublicensees
Bristows appoints new joint managing partner
Bristows has announced that competition law expert Stephen Smith will be the new joint managing partner of the firm
SCOTUS invites govt comment on Teva clash
Court opens door for US solicitor general to file a brief | Hard fought ‘skinny label’ case centres on a generic medicine maker excluding patent-protected indications from its labels.
